# Xperi Inc.: financial statements, quarterly

XPER · NYSE · CIK 1788999 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xper.md) · [Financials](/companies/xper/financials.md) · [Filings](/companies/xper/filings.md) · [Insiders](/companies/xper/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xper/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [130](/filings/0000950170-24-123424.md) | [137 d](/filings/0001193125-26-076849.md) | [119](/filings/0000950170-25-067036.md) | [120](/filings/0000950170-25-105049.md) | [133](/filings/0001193125-25-269600.md) | [122 d](/filings/0001193125-26-076849.md) | [114](/filings/0001788999-26-000013.md) | [106](/filings/0001788999-26-000018.md) | [112](/filings/0001193125-25-269600.md) | [117 d](/filings/0001193125-26-076849.md) | [114](/filings/0001788999-26-000013.md) | [114](/filings/0001788999-26-000018.md) |
| Research and development | $m | [56.4](/filings/0000950170-24-123424.md) | [55.8 d](/filings/0001193125-26-076849.md) | [50.4](/filings/0000950170-25-067036.md) | [45.1](/filings/0000950170-25-105049.md) | [53.6](/filings/0001193125-25-269600.md) | [42.2 d](/filings/0001193125-26-076849.md) | [39.5](/filings/0001788999-26-000013.md) | [29.8](/filings/0001788999-26-000018.md) | [29.9](/filings/0001193125-25-269600.md) | [35.8 d](/filings/0001193125-26-076849.md) | [27.1](/filings/0001788999-26-000013.md) | [21.8](/filings/0001788999-26-000018.md) |
| Selling, general and administrative | $m | [59.6](/filings/0000950170-24-123424.md) | [59.5 d](/filings/0001193125-26-076849.md) | [56.4](/filings/0000950170-25-067036.md) | [53.1](/filings/0000950170-25-105049.md) | [56.5](/filings/0001193125-25-269600.md) | [52.2 d](/filings/0001193125-26-076849.md) | [48.7](/filings/0001788999-26-000013.md) | [41.1](/filings/0001788999-26-000018.md) | [42.5](/filings/0001193125-25-269600.md) | [49.5 d](/filings/0001193125-26-076849.md) | [41.8](/filings/0001788999-26-000013.md) | [41.5](/filings/0001788999-26-000018.md) |
| Operating income | $m | [(31.1)](/filings/0000950170-24-123424.md) | [(29.8) d](/filings/0001193125-26-076849.md) | [(32.3)](/filings/0000950170-25-067036.md) | [(21.9)](/filings/0000950170-25-105049.md) | [(18.6)](/filings/0001193125-25-269600.md) | [(14.3) d](/filings/0001193125-26-076849.md) | [(16.4)](/filings/0001788999-26-000013.md) | [(11.1)](/filings/0001788999-26-000018.md) | [(1.4)](/filings/0001193125-25-269600.md) | [(14.8) d](/filings/0001193125-26-076849.md) | [2.2](/filings/0001788999-26-000013.md) | [2.9](/filings/0001788999-26-000018.md) |
| Interest expense | $m | [0.8](/filings/0000950170-24-123424.md) | [0.8 d](/filings/0001193125-26-076849.md) | [0.7](/filings/0000950170-25-067036.md) | [0.7](/filings/0000950170-25-105049.md) | [0.8](/filings/0001193125-25-269600.md) | [0.8 d](/filings/0001193125-26-076849.md) | [0.7](/filings/0001788999-26-000013.md) | [0.8](/filings/0001788999-26-000018.md) | [0.8](/filings/0001193125-25-269600.md) | [0.7 d](/filings/0001193125-26-076849.md) | [0.7](/filings/0001788999-26-000013.md) | [0.7](/filings/0001788999-26-000018.md) |
| Income tax | $m | [9.7](/filings/0000950170-24-123424.md) | [(4.4) d](/filings/0001193125-26-076849.md) | [4.3](/filings/0000950170-25-067036.md) | [9.3](/filings/0000950170-25-105049.md) | [2.9](/filings/0001193125-25-269600.md) | [(4.0) d](/filings/0001193125-26-076849.md) | [3.5](/filings/0001788999-26-000013.md) | [4.6](/filings/0001788999-26-000018.md) | [4.8](/filings/0001193125-25-269600.md) | [2.8 d](/filings/0001193125-26-076849.md) | [10.1](/filings/0001788999-26-000013.md) | [4.8](/filings/0001788999-26-000018.md) |
| Net income | $m | [(41.4)](/filings/0000950170-24-123424.md) | [(24.8) d](/filings/0001193125-26-076849.md) | [(13.1)](/filings/0000950170-25-067036.md) | [(30.3)](/filings/0000950170-25-105049.md) | [(16.8)](/filings/0001193125-25-269600.md) | [46.2 d](/filings/0001193125-26-076849.md) | [(18.4)](/filings/0000950170-25-067036.md) | [(14.8)](/filings/0001788999-26-000018.md) | [(6.1)](/filings/0001193125-25-269600.md) | [(17.1) d](/filings/0001193125-26-076849.md) | [(7.8)](/filings/0001788999-26-000013.md) | [(1.5)](/filings/0001788999-26-000018.md) |
| Diluted EPS | $ per share | [(0.96)](/filings/0000950170-24-123424.md) | not reported | [(0.29)](/filings/0000950170-25-067036.md) | [(0.67)](/filings/0000950170-25-105049.md) | [(0.37)](/filings/0001193125-25-269600.md) | not reported | [(0.41)](/filings/0001788999-26-000013.md) | [(0.32)](/filings/0001788999-26-000018.md) | [(0.13)](/filings/0001193125-25-269600.md) | not reported | [(0.17)](/filings/0001788999-26-000013.md) | [(0.03)](/filings/0001788999-26-000018.md) |
| Basic EPS | $ per share | [(0.96)](/filings/0000950170-24-123424.md) | not reported | [(0.29)](/filings/0000950170-25-067036.md) | [(0.67)](/filings/0000950170-25-105049.md) | [(0.37)](/filings/0001193125-25-269600.md) | not reported | [(0.41)](/filings/0001788999-26-000013.md) | [(0.32)](/filings/0001788999-26-000018.md) | [(0.13)](/filings/0001193125-25-269600.md) | not reported | [(0.17)](/filings/0001788999-26-000013.md) | [(0.03)](/filings/0001788999-26-000018.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [132](/filings/0000950170-23-063029.md) | [142](/filings/0001193125-26-076849.md) | [95.2](/filings/0000950170-24-057019.md) | [92.5](/filings/0000950170-24-094002.md) | [72.7](/filings/0000950170-24-123424.md) | [131](/filings/0001193125-26-076849.md) | [88.0](/filings/0000950170-25-067036.md) | [95.1](/filings/0000950170-25-105049.md) | [96.8](/filings/0001193125-25-269600.md) | [96.8](/filings/0001788999-26-000018.md) | [70.4](/filings/0001788999-26-000013.md) | [90.6](/filings/0001788999-26-000018.md) |
| Current assets | $m | [296](/filings/0000950170-23-063029.md) | [317](/filings/0000950170-25-029159.md) | [272](/filings/0000950170-24-057019.md) | [266](/filings/0000950170-24-094002.md) | [259](/filings/0000950170-24-123424.md) | [305](/filings/0001193125-26-076849.md) | [267](/filings/0000950170-25-067036.md) | [284](/filings/0000950170-25-105049.md) | [273](/filings/0001193125-25-269600.md) | [267](/filings/0001788999-26-000018.md) | [261](/filings/0001788999-26-000013.md) | [284](/filings/0001788999-26-000018.md) |
| Total assets | $m | [664](/filings/0000950170-23-063029.md) | [674](/filings/0000950170-25-029159.md) | [630](/filings/0000950170-24-057019.md) | [619](/filings/0000950170-24-094002.md) | [616](/filings/0000950170-24-123424.md) | [668](/filings/0001193125-26-076849.md) | [633](/filings/0000950170-25-067036.md) | [629](/filings/0000950170-25-105049.md) | [629](/filings/0001193125-25-269600.md) | [616](/filings/0001788999-26-000018.md) | [607](/filings/0001788999-26-000013.md) | [616](/filings/0001788999-26-000018.md) |
| Current liabilities | $m | [151](/filings/0000950170-23-063029.md) | [165](/filings/0000950170-25-029159.md) | [130](/filings/0000950170-24-057019.md) | [133](/filings/0000950170-24-094002.md) | [201](/filings/0000950170-24-123424.md) | [185](/filings/0001193125-26-076849.md) | [118](/filings/0000950170-25-067036.md) | [113](/filings/0000950170-25-105049.md) | [113](/filings/0001193125-25-269600.md) | [111](/filings/0001788999-26-000018.md) | [110](/filings/0001788999-26-000013.md) | [114](/filings/0001788999-26-000018.md) |
| Total liabilities | $m | [278](/filings/0000950170-23-063029.md) | [287](/filings/0000950170-25-029159.md) | [249](/filings/0000950170-24-057019.md) | [249](/filings/0000950170-24-094002.md) | [260](/filings/0000950170-24-123424.md) | [239](/filings/0001193125-26-076849.md) | [215](/filings/0000950170-25-067036.md) | [209](/filings/0000950170-25-105049.md) | [208](/filings/0001193125-25-269600.md) | [202](/filings/0001788999-26-000018.md) | [199](/filings/0001788999-26-000013.md) | [201](/filings/0001788999-26-000018.md) |
| Long-term debt | $m | [50.0](/filings/0000950170-23-063029.md) | [50.0](/filings/0000950170-25-029159.md) | [50.0](/filings/0000950170-24-057019.md) | [50.0](/filings/0000950170-24-094002.md) | [27.7](/filings/0000950170-24-123424.md) | [0.0](/filings/0001193125-26-076849.md) | [40.0](/filings/0000950170-25-067036.md) | [40.0](/filings/0000950170-25-105049.md) | [40.0](/filings/0001193125-25-269600.md) | [40.0](/filings/0001788999-26-000018.md) | [40.0](/filings/0001788999-26-000013.md) | [40.0](/filings/0001788999-26-000018.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | [50.0](/filings/0000950170-24-123424.md) | [50.0](/filings/0001193125-26-076849.md) | not reported | [0.0](/filings/0000950170-25-105049.md) | [0.0](/filings/0001193125-25-269600.md) | [0.0](/filings/0001193125-26-076849.md) | not reported | not reported |
| Shareholders' equity | $m | [403](/filings/0000950170-23-063029.md) | [404](/filings/0000950170-25-029159.md) | [399](/filings/0000950170-24-057019.md) | [389](/filings/0000950170-24-094002.md) | [377](/filings/0000950170-24-123424.md) | [429](/filings/0000950170-25-029159.md) | [419](/filings/0001788999-26-000018.md) | [420](/filings/0001788999-26-000018.md) | [421](/filings/0001193125-25-269600.md) | [414](/filings/0001788999-26-000018.md) | [408](/filings/0001788999-26-000018.md) | [415](/filings/0001788999-26-000018.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [24.0 d](/filings/0000950170-24-123424.md) | [20.7 d](/filings/0001193125-26-076849.md) | [(49.8)](/filings/0000950170-25-067036.md) | [(2.1) d](/filings/0000950170-25-105049.md) | [(4.6) d](/filings/0001193125-25-269600.md) | [1.2 d](/filings/0001193125-26-076849.md) | [(22.3)](/filings/0001788999-26-000013.md) | [10.1 d](/filings/0001788999-26-000018.md) | [7.5 d](/filings/0001193125-25-269600.md) | [4.1 d](/filings/0001193125-26-076849.md) | [(18.0)](/filings/0001788999-26-000013.md) | [14.6 d](/filings/0001788999-26-000018.md) |
| Capital expenditure | $m | [2.2 d](/filings/0000950170-24-123424.md) | [2.1 d](/filings/0001193125-26-076849.md) | [1.8](/filings/0000950170-25-067036.md) | [0.5 d](/filings/0000950170-25-105049.md) | [1.0 d](/filings/0001193125-25-269600.md) | [1.7 d](/filings/0001193125-26-076849.md) | [1.1](/filings/0001788999-26-000013.md) | [0.6 d](/filings/0001788999-26-000018.md) | [0.8 d](/filings/0001193125-25-269600.md) | [2.9 d](/filings/0001193125-26-076849.md) | [1.1](/filings/0001788999-26-000013.md) | [0.5 d](/filings/0001788999-26-000018.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [10.0 d](/filings/0001193125-26-076849.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-076849.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.0](/filings/0000950170-23-063029.md) | [42.2](/filings/0000950170-24-057019.md) | [42.8](/filings/0000950170-24-094002.md) | [43.3](/filings/0000950170-24-123424.md) | [44.5](/filings/0000950170-25-067036.md) | [45.3](/filings/0000950170-25-105049.md) | [45.7](/filings/0001193125-25-269600.md) | [44.8](/filings/0001788999-26-000013.md) | [45.8](/filings/0001788999-26-000018.md) | [46.3](/filings/0001193125-25-269600.md) | [47.4](/filings/0001788999-26-000013.md) | [48.4](/filings/0001788999-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,771,822 at 2026-07-27, from the cover of the [10-Q filed 2026-08-06](/filings/0001788999-26-000018.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.